Suppr超能文献

当代外周动脉疾病的医学管理

Contemporary Medical Management of Peripheral Artery Disease.

机构信息

Division of Cardiology, CPC Clinical Research, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO (M.P.B.).

Department of Medicine, Whitaker Cardiovascular Institute, Boston University School of Medicine, Section of Vascular Biology, Boston Medical Center, MA (N.M.H.).

出版信息

Circ Res. 2021 Jun 11;128(12):1868-1884. doi: 10.1161/CIRCRESAHA.121.318258. Epub 2021 Jun 10.

Abstract

Peripheral artery disease (PAD) is a manifestation of systemic atherosclerosis. Modifiable risk factors including cigarette smoking, dyslipidemia, diabetes, poor diet quality, obesity, and physical inactivity, along with underlying genetic factors contribute to lower extremity atherosclerosis. Patients with PAD often have coexistent coronary or cerebrovascular disease, and increased likelihood of major adverse cardiovascular events, including myocardial infarction, stroke and cardiovascular death. Patients with PAD often have reduced walking capacity and are at risk of acute and chronic critical limb ischemia leading to major adverse limb events, such as peripheral revascularization or amputation. The presence of polyvascular disease identifies the highest risk patient group for major adverse cardiovascular events, and patients with prior critical limb ischemia, prior lower extremity revascularization, or amputation have a heightened risk of major adverse limb events. Medical therapies have demonstrated efficacy in reducing the risk of major adverse cardiovascular events and major adverse limb events, and improving function in patients with PAD by modulating key disease determining pathways including inflammation, vascular dysfunction, and metabolic disturbances. Treatment with guideline-recommended therapies, including smoking cessation, lipid lowering drugs, optimal glucose control, and antithrombotic medications lowers the incidence of major adverse cardiovascular events and major adverse limb events. Exercise training and cilostazol improve walking capacity. The heterogeneity of risk profile in patients with PAD supports a personalized approach, with consideration of treatment intensification in those at high risk of adverse events. This review highlights the medical therapies currently available to improve outcomes in patients with PAD.

摘要

外周动脉疾病(PAD)是全身性动脉粥样硬化的一种表现。可改变的危险因素包括吸烟、血脂异常、糖尿病、不良饮食质量、肥胖和缺乏身体活动,以及潜在的遗传因素,这些都导致下肢动脉粥样硬化。PAD 患者常伴有并存的冠状动脉或脑血管疾病,以及发生主要不良心血管事件(包括心肌梗死、中风和心血管死亡)的风险增加。PAD 患者的步行能力通常会降低,并且存在急性和慢性临界肢体缺血的风险,导致主要不良肢体事件,如外周血管重建或截肢。多血管疾病的存在确定了发生主要不良心血管事件的最高风险患者群体,而有既往临界肢体缺血、既往下肢血管重建或截肢的患者,发生主要不良肢体事件的风险更高。通过调节炎症、血管功能障碍和代谢紊乱等关键疾病决定途径,医学治疗已证明在降低主要不良心血管事件和主要不良肢体事件风险以及改善 PAD 患者功能方面的疗效。采用指南推荐的治疗方法,包括戒烟、降脂药物、最佳血糖控制和抗血栓药物,可降低主要不良心血管事件和主要不良肢体事件的发生率。运动训练和西洛他唑可提高步行能力。PAD 患者的风险状况存在异质性,支持采用个性化方法,对高风险不良事件患者考虑强化治疗。本综述重点介绍了目前可用于改善 PAD 患者结局的医学治疗方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验